Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1995-12-22
|
| pubmed:abstractText |
Interferons (IFNs) augment the effect of some antitumor agents, including cis-diamminedichloroplatinum(II) (cDDP), in experimental systems. The effect of human recombinant interferon-alpha 2b (rIFN alpha) on the cDDP-dependent growth delay of a human non-small cell lung cancer established as a xenograft in nude mice (NX002) has been investigated. IFN (10(5) IU/mouse, s.c.) as a single agent had no effect on the growth of the xenograft. cDDP (4.2 mg/kg, i.p.) caused a specific growth delay of 0.42, and this delay was significantly enhanced (to 1.08) by concomitant dosing with the otherwise inactive IFN. Possible mechanisms for this supra-additive relationship between IFN and cDDP have been investigated: increased intratumoral accumulation of platinum was seen at late time points (maximally at 36 hr) during the pharmacokinetic beta-phase of cDDP elimination from the plasma of the nude mice. Tumor:plasma platinum concentration ratios at 36-48 hr indicated significantly increased accumulation of platinum in tumors from IFN-treated mice compared to controls (p < 0.05). Scheduling experiments suggest that this IFN-mediated effect can persist for 4 hr. These differences may account for the enhanced antitumor activity of cDDP when coadministered with IFN.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0735-7907
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
595-603
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7583709-Animals,
pubmed-meshheading:7583709-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7583709-Body Temperature,
pubmed-meshheading:7583709-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:7583709-Cell Division,
pubmed-meshheading:7583709-Cisplatin,
pubmed-meshheading:7583709-Drug Administration Schedule,
pubmed-meshheading:7583709-Drug Synergism,
pubmed-meshheading:7583709-Female,
pubmed-meshheading:7583709-Humans,
pubmed-meshheading:7583709-Interferon Type I,
pubmed-meshheading:7583709-Kidney,
pubmed-meshheading:7583709-Lung Neoplasms,
pubmed-meshheading:7583709-Male,
pubmed-meshheading:7583709-Mice,
pubmed-meshheading:7583709-Mice, Nude,
pubmed-meshheading:7583709-Neoplasm Transplantation,
pubmed-meshheading:7583709-Recombinant Proteins,
pubmed-meshheading:7583709-Transplantation, Heterologous
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Effect of human recombinant interferon-alpha on the activity of cis-diamminedichloroplatinum(II) in human non-small cell lung cancer xenografts.
|
| pubmed:affiliation |
Medical Oncology Unit Western General Hospital, Edinburgh, Scotland.
|
| pubmed:publicationType |
Journal Article
|